JPMorgan Reinstates Insmed (INSM) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $112.58 +0.89%
Rating Summary:
31 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
31 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Insmed (NASDAQ: INSM) with a Overweight rating and a price target of $36.00.
For an analyst ratings summary and ratings history on Insmed click here. For more ratings news on Insmed click here.
Shares of Insmed closed at $24.82 yesterday.
You May Also Be Interested In
- Goldman Sachs: 'we see INSM as an attractive growth story positioned for a re-rating'
- Increasing unusual option volume: PBRA ISNM RCL EVGO TRV PPG
- Needham Starts Kazia Therapeutics (KZIA) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
